One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
The Discovery of Hepatitis C — The 2020 Nobel Prize in Physiology or Medicine
Jay H. Hoofnagle, M.D., and Stephen M. Feinstone, M.D.
doi : 10.1056/NEJMp2031110
N Engl J Med 2020; 383:2297-2299
Broken Promises — How Medicare Part D Has Failed to Deliver Savings to Older Adults
Stacie B. Dusetzina, Ph.D., Benyam Muluneh, Pharm.D., Nancy L. Keating, M.D., M.P.H., and Haiden A. Huskamp, Ph.D.
doi : 10.1056/NEJMp2027580
N Engl J Med 2020; 383:2299-2301
A Pandemic within a Pandemic — Intimate Partner Violence during Covid-19
Megan L. Evans, M.D., M.P.H., Margo Lindauer, J.D., and Maureen E. Farrell, M.D.
doi : 10.1056/NEJMp2024046
N Engl J Med 2020; 383:2302-2304
Preterm Birth and 17OHP — Why the FDA Should Not Withdraw Approval
Michael F. Greene, M.D., Mark A. Klebanoff, M.D., M.P.H., and David Harrington, Ph.D.
doi : 10.1056/NEJMp2031727
N Engl J Med 2020; 383:e130
Withdrawing Approval of Makena — A Proposal from the FDA Center for Drug Evaluation and Research
Christina Y. Chang, M.D., M.P.H., Christine P. Nguyen, M.D., Barbara Wesley, M.D., M.P.H., Jia Guo, Ph.D., Laura Lee Johnson, Ph.D., and Hylton V. Joffe, M.D., M.M.Sc.
doi : 10.1056/NEJMp2031055
N Engl J Med 2020; 383:e131
Evinacumab in Patients with Refractory Hypercholesterolemia
Robert S. Rosenson, M.D., Lesley J. Burgess, M.D., Ph.D., Christoph F. Ebenbichler, M.D., Seth J. Baum, M.D., Erik S.G. Stroes, M.D., Ph.D., Shazia Ali, Pharm.D., Nagwa Khilla, M.S., Robert Hamlin, B.S., Robert Pordy, M.D., Yuping Dong, Ph.D., Vladimir Son, Ph.D., and Daniel Gaudet, M.D., Ph.D.
doi : 10.1056/NEJMoa2031049
N Engl J Med 2020; 383:2307-2319
Patients with refractory hypercholesterolemia, who have high low-density lipoprotein (LDL) cholesterol levels despite treatment with lipid-lowering therapies at maximum tolerated doses, have an increased risk of atherosclerosis. In such patients, the efficacy and safety of subcutaneous and intravenous evinacumab, a fully human monoclonal antibody against angiopoietin-like 3, are not known.
Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine
Cheryl Keech, M.D., Ph.D., Gary Albert, M.S., Iksung Cho, M.S., Andreana Robertson, M.S., Patricia Reed, B.S., Susan Neal, Joyce S. Plested, Ph.D., Mingzhu Zhu, Ph.D., Shane Cloney-Clark, B.S., Haixia Zhou, Ph.D., Gale Smith, Ph.D., Nita Patel, M.S.,
doi : 10.1056/NEJMoa2026920
N Engl J Med 2020; 383:2320-2332
NVX-CoV2373 is a recombinant severe acute respiratory syndrome coronavirus 2 (rSARS-CoV-2) nanoparticle vaccine composed of trimeric full-length SARS-CoV-2 spike glycoproteins and Matrix-M1 adjuvant.
Efficacy of Tocilizumab in Patients Hospitalized with Covid-19
John H. Stone, M.D., M.P.H., Matthew J. Frigault, M.D., Naomi J. Serling-Boyd, M.D., Ana D. Fernandes, M.A., Liam Harvey, B.S., Andrea S. Foulkes, Ph.D., Nora K. Horick, M.S., Brian C. Healy, Ph.D., Ruta Shah, M.D., Ana Maria Bensaci, M.D., Ann E. Woolley, M.D., Sarah Nikiforow, M.D., Ph.D.,
doi : 10.1056/NEJMoa2028836
N Engl J Med 2020; 383:2333-2344
The efficacy of interleukin-6 receptor blockade in hospitalized patients with coronavirus disease 2019 (Covid-19) who are not receiving mechanical ventilation is unclear.
Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer
Maha Hussain, M.D., Joaquin Mateo, M.D., Karim Fizazi, M.D., Fred Saad, M.D., Neal Shore, M.D., Shahneen Sandhu, M.D., Kim N. Chi, M.D., Oliver Sartor, M.D., Neeraj Agarwal, M.D., David Olmos, M.D., Antoine Thiery-Vuillemin, M.D., Przemyslaw Twardowski, M.D.,
doi : 10.1056/NEJMoa2022485
N Engl J Med 2020; 383:2345-2357
We previously reported that olaparib led to significantly longer imaging-based progression-free survival than the physician’s choice of enzalutamide or abiraterone among men with metastatic castration-resistant prostate cancer who had qualifying alterations in homologous recombination repair genes and whose disease had progressed during previous treatment with a next-generation hormonal agent. The results of the final analysis of overall survival have not yet been reported.
Spontaneous Coronary-Artery Dissection
Esther S.H. Kim, M.D., M.P.H.
doi : 10.1056/NEJMra2001524
N Engl J Med 2020; 383:2358-2370
Examination of the Neck Veins
Taweevat Assavapokee, M.D., and Kunlawat Thadanipon, M.D.
doi : 10.1056/NEJMvcm1806474
N Engl J Med 2020; 383:e132
Renal Cryptococcosis
Lina Espinosa Saltarén, M.D., and Rafael Andrade Pérez, M.D.
doi : 10.1056/NEJMicm2007464
N Engl J Med 2020; 383:2371
Iridociliary Melanoma
Stephanie Lemaitre, M.D., Ph.D., and Amit Arora, M.B., B.S.
doi : 10.1056/NEJMicm2012968
N Engl J Med 2020; 383:e133
Case 38-2020: A 52-Year-Old Man with Cancer and Acute Hypoxemia
Lucas X. Marinacci, M.D., F. Joseph Simeone, M.D., Andrew L. Lundquist, M.D., Ph.D., David J. Kuter, M.D., D.Phil., and Grace K. Mahowald, M.D., Ph.D.
doi : 10.1056/NEJMcpc2004991
N Engl J Med 2020; 383:2372-2383
Factoring in ANGPTL3 When LDL Is Refractory
Seth S. Martin, M.D., M.H.S.
doi : 10.1056/NEJMe2032798
N Engl J Med 2020; 383:2385-2386
Tocilizumab for Covid-19 — The Ongoing Search for Effective Therapies
Edmund Huang, M.D., and Stanley C. Jordan, M.D.
doi : 10.1056/NEJMe2032071
N Engl J Med 2020; 383:2387-2388
Audio Interview: SARS-CoV-2 Vaccination and Vulnerable Populations
Eric J. Rubin, M.D., Ph.D., Lindsey R. Baden, M.D., Joshua A. Barocas, M.D., and Stephen Morrissey, Ph.D.
doi : 10.1056/NEJMe2034906
N Engl J Med 2020; 383:e143
Covid-19–Associated Myopathy Caused by Type I Interferonopathy
doi : 10.1056/NEJMc2031085
N Engl J Med 2020; 383:2389-2390
Effect of Diet versus Gastric Bypass on Metabolic Function in Diabetes
doi : 10.1056/NEJMc2030030
N Engl J Med 2020; 383:2390-2394
The Death of Daniel Prude — Reflections of a Black Neurosurgeon
David A. Paul, M.D.
doi : 10.1056/NEJMpv2030234
N Engl J Med 2020; 383:e135
